6.64
Diamedica Therapeutics Inc stock is traded at $6.64, with a volume of 381.27K.
It is down -5.41% in the last 24 hours and down -6.87% over the past month.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
See More
Previous Close:
$7.02
Open:
$6.97
24h Volume:
381.27K
Relative Volume:
0.97
Market Cap:
$343.21M
Revenue:
-
Net Income/Loss:
$-19.90M
P/E Ratio:
-12.53
EPS:
-0.53
Net Cash Flow:
$-19.80M
1W Performance:
-6.08%
1M Performance:
-6.87%
6M Performance:
+89.17%
1Y Performance:
+50.23%
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Name
Diamedica Therapeutics Inc
Sector
Industry
Phone
(763) 496-5454
Address
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
DMAC
Diamedica Therapeutics Inc
|
6.64 | 362.86M | 0 | -19.90M | -19.80M | -0.53 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-07-24 | Initiated | H.C. Wainwright | Buy |
Apr-24-24 | Resumed | Craig Hallum | Buy |
Jun-22-23 | Upgrade | Oppenheimer | Perform → Outperform |
Apr-09-21 | Initiated | Oppenheimer | Outperform |
Feb-17-21 | Initiated | ROTH Capital | Buy |
Oct-30-20 | Initiated | Guggenheim | Buy |
Jul-08-20 | Initiated | Maxim Group | Buy |
Apr-30-19 | Initiated | Dougherty & Company | Buy |
Mar-05-19 | Initiated | Lake Street | Buy |
View All
Diamedica Therapeutics Inc Stock (DMAC) Latest News
How risky is DiaMedica Therapeutics Inc. stock nowJuly 2025 Pullbacks & Daily Stock Trend Watchlist - newser.com
Is DiaMedica Therapeutics Inc. stock bottoming outJuly 2025 Opening Moves & Low Risk Entry Point Guides - newser.com
How hedge fund analytics apply to DiaMedica Therapeutics Inc. stockEarnings Summary Report & Real-Time Sentiment Analysis - newser.com
DiaMedica Therapeutics' (DMAC) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Is it too late to sell DiaMedica Therapeutics Inc.July 2025 Weekly Recap & Technical Pattern Based Buy Signals - newser.com
Can DiaMedica Therapeutics Inc. stock continue upward trendJuly 2025 Update & Low Drawdown Trading Techniques - newser.com
After Golden Cross, DiaMedica Therapeutics, Inc. (DMAC)'s Technical Outlook is Bright - MSN
Is DiaMedica Therapeutics Inc a good long term investmentHealthcare Stock Analysis & Superior Capital Growth - earlytimes.in
DiaMedica Therapeutics (NASDAQ:DMAC) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Will DiaMedica Therapeutics Inc. bounce back from current support2025 Market Overview & High Accuracy Swing Entry Alerts - newser.com
DiaMedica Therapeutics Inc. stock volume spike explainedRate Cut & Daily Profit Maximizing Trade Tips - newser.com
Published on: 2025-10-03 00:24:41 - newser.com
Published on: 2025-10-02 18:46:41 - newser.com
Perigon Wealth Management LLC Acquires Shares of 53,000 DiaMedica Therapeutics, Inc. $DMAC - MarketBeat
Tick level data insight on DiaMedica Therapeutics Inc. volatilityJuly 2025 News Drivers & Verified Swing Trading Watchlist - newser.com
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Published on: 2025-09-29 10:18:49 - newser.com
What analysts say about DiaMedica Therapeutics Inc stockContrarian Investment Ideas & Free Superior Stock Performance - Early Times
How DiaMedica Therapeutics Inc. stock reacts to oil prices2025 Winners & Losers & Daily Growth Stock Investment Tips - newser.com
DiaMedica Therapeutics, Inc. $DMAC Shares Bought by Goldman Sachs Group Inc. - MarketBeat
DiaMedica Therapeutics (NASDAQ:DMAC) Lowered to “Sell” Rating by Wall Street Zen - Defense World
DiaMedica Therapeutics (NASDAQ:DMAC) Downgraded by Wall Street Zen to Sell - MarketBeat
Best Momentum Stocks to Buy for October 14th - MSN
Using portfolio simulators with DiaMedica Therapeutics Inc. includedJuly 2025 Decliners & Long-Term Growth Plans - newser.com
Published on: 2025-09-22 10:09:38 - newser.com
Diamedica Therapeutics Inc Stock (DMAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Diamedica Therapeutics Inc Stock (DMAC) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
STAHLBERG JAN | 10% Owner |
Aug 13 '25 |
Buy |
5.91 |
293,601 |
1,734,918 |
7,058,066 |
STAHLBERG JAN | 10% Owner |
Aug 14 '25 |
Buy |
5.99 |
70,414 |
421,921 |
7,128,480 |
STAHLBERG JAN | 10% Owner |
Aug 20 '25 |
Buy |
5.86 |
71,107 |
416,495 |
7,207,820 |
STAHLBERG JAN | 10% Owner |
Aug 26 '25 |
Buy |
6.00 |
59,648 |
357,888 |
7,713,693 |
STAHLBERG JAN | 10% Owner |
Aug 22 '25 |
Buy |
5.96 |
59,788 |
356,576 |
7,315,780 |
STAHLBERG JAN | 10% Owner |
Aug 27 '25 |
Buy |
6.00 |
50,772 |
304,632 |
7,764,465 |
STAHLBERG JAN | 10% Owner |
Aug 21 '25 |
Buy |
5.96 |
48,172 |
287,028 |
7,255,992 |
STAHLBERG JAN | 10% Owner |
Aug 15 '25 |
Buy |
6.00 |
8,233 |
49,398 |
7,136,713 |
STAHLBERG JAN | 10% Owner |
Jul 23 '25 |
Buy |
3.50 |
1,542,857 |
5,400,000 |
6,764,465 |
Von Koch Thomas | 10% Owner |
Jul 23 '25 |
Buy |
3.50 |
2,857,142 |
9,999,997 |
8,383,577 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):